4/1
08:00 am
mnpr
Monopar Therapeutics Inc. (NASDAQ: MNPR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $40.00 price target on the stock.
Medium
Report
Monopar Therapeutics Inc. (NASDAQ: MNPR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $40.00 price target on the stock.